Teleflex's TFX robust performance in the Interventional product line is poised to help it grow in the upcoming quarters. The Urolift system is seeing consistent growth in hospitals, with positive ...

Teleflex’s TFX Interventional Urology portfolio is well positioned for sustained growth, led by UroLift’s expanding global footprint and strong clinical differentiation. Supported by favorable ...

Shares of Teleflex Inc. TFX rallied 2.55% to $112.81 Friday, on what proved to be an all-around positive trading session for ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Shares of medical technology company Teleflex (NYSE:TFX) fell 22.9% in the morning session after the company reported ...

Teleflex (NYSE:TFX) is slated for expansion in the coming quarters, owing to the key growth drivers in the Interventional business. The company's market dominance in Central Venous Catheters and ...

Teleflex announced a major leadership transition effective January 7–8, 2026, with long-time Chairman, President and CEO Liam Kelly departing and board member Stuart Randle, a veteran medical device ...

On August 1, Teleflex will release earnings for the most recent quarter. Analysts on Wall Street expect Teleflex will release earnings per share of $3.33. Track Teleflex stock price in real-time on ...

Teleflex Incorporated, a diversified medical device company, saw a 17% stock drop after Q3 results in late October. The stock now trades at under 13.5 EPS (non-GAAP) and at the equity's lowest ...

Teleflex (NYSE:TFX – Free Report) had its price objective lowered by Mizuho from $150.00 to $130.00 in a research report released on Wednesday,Benzinga reports. The brokerage currently has a neutral ...